Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) with unknown etiology in which gradual fibrotic scarring of the lungs leads to usual interstitial pneumonia (UIP) and, ultimately, to death. IPF affects three million people worldwide, and the only currently available treatments include the antifibrotic drugs nintedanib and pirfenidone, which effectively reduce fibrosis progression are, unfortunately, not effective in curing the disease. In recent years, the paradigm of IPF pathogenesis has shifted from a fibroblast-driven disease to an epithelium-driven disease, wherein, upon recurrent microinjuries, dysfunctional alveolar type II epithelial cells (ATII) are not only unable to sustain physiological lung regeneration but also promote aberrant epithelial–mesenchymal crosstalk. This creates a drift towards fibrosis rather than regeneration. In the context of this review article, we discuss the most relevant mechanisms involved in IPF pathogenesis with a specific focus on the role of dysfunctional ATII cells in promoting disease progression. In particular, we summarize the main causes of ATII cell dysfunction, such as aging, environmental factors, and genetic determinants. Next, we describe the known mechanisms of physiological lung regeneration by drawing a parallel between embryonic lung development and the known pathways involved in ATII-driven alveolar re-epithelization after injury. Finally, we review the most relevant interventional clinical trials performed in the last 20 years with the aim of underlining the urgency of developing new therapies against IPF that are not only aimed at reducing disease progression by hampering ECM deposition but also boost the physiological processes of ATII-driven alveolar regeneration.

Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis

Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis

The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis Via Differential Cellular Pathways

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis

Evolving Perspectives on Innate Immune Mechanisms of IPF

The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis

Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Emerging role of immune cells as drivers of pulmonary fibrosis

Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis

Pathology of idiopathic pulmonary fibrosis with particular focus on vascular endothelium and epithelial injury and their therapeutic potential

Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions

Epithelial–Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis

Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets

Idiopathic Pulmonary Fibrosis: A Disorder of Epithelial Cell Dysfunction

Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects

Idiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review

The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis